Biang Jang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Biang Jang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Tsourkas
University of Pennsylvania
2 shared publications - Lesan Yan
State Key Laboratory of Advanced Technology for Materials Synthesis and Processing
2 shared publications - Ahmad Amirshaghaghi
Department of Bioengineering
1 shared publication - Burcin Altun Ozdemir
Department of Bioengineering, University of Pennsylvania, 210 S. 33rd Street, 240 Skirkanich Hall, Philadelphia, PA 19104, USA
1 shared publication - Elizabeth Higbee-Dempsey
Developmental Therapeutics Core, Northwestern University, Evanston, USA
1 shared publication - Fabiana Zappala
Department of Bioengineering, University of Pennsylvania, 210 S. 33rd Street, 240 Skirkanich Hall, Philadelphia, PA 19104, USA
1 shared publication
Latest Publications
- Open Access
- 6 May 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (18) , eabn4613
Rapid, site-specific labeling of “off-the-shelf” and native serum autoantibodies with T cell–redirecting domains
Extensive antibody engineering and cloning is typically required to generate new bispecific antibodies. Made-to-order genes, advanced expression systems, and high-efficiency cloning can simplify and accelerate this process, but it still can take months before a functional product is realized. We developed a simple method to site-specifically and covalently attach a T cell–redirecting domain to any off-the-shelf, human immunoglobulin G (IgG) or native IgG isolated from serum. No antibody engineering, cloning, or knowledge of the antibody sequence is required. Bispecific antibodies are generated in just hours. By labeling antibodies isolated from tumor-bearing mice, including two syngeneic models, we generated T cell–redirecting autoantibodies (TRAAbs) that act as an effective therapeutic. TRAAbs preferentially bind tumor tissue over healthy tissue, indicating a previously unexplored therapeutic window. The use of autoantibodies to direct the tumor targeting of bispecific antibodies represents a new paradigm in personalized medicine that eliminates the need to identify tumor biomarkers.
- 6 May 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (18) , eabn4613
Open AccessRapid, site-specific labeling of “off-the-shelf” and native serum autoantibodies with T cell–redirecting domains
Extensive antibody engineering and cloning is typically required to generate new bispecific antibodies. Made-to-order genes, advanced expression systems, and high-efficiency cloning can simplify and accelerate this process, but it still can take months before a functional product is realized. We developed a simple method to site-specifically and covalently attach a T cell–redirecting domain to any off-the-shelf, human immunoglobulin G (IgG) or native IgG isolated from serum. No antibody engineering, cloning, or knowledge of the antibody sequence is required. Bispecific antibodies are generated in just hours. By labeling antibodies isolated from tumor-bearing mice, including two syngeneic models, we generated T cell–redirecting autoantibodies (TRAAbs) that act as an effective therapeutic. TRAAbs preferentially bind tumor tissue over healthy tissue, indicating a previously unexplored therapeutic window. The use of autoantibodies to direct the tumor targeting of bispecific antibodies represents a new paradigm in personalized medicine that eliminates the need to identify tumor biomarkers.
- Open Access
- 9 April 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (15) , eabe6374
Phospholipase A 2 inhibitor–loaded micellar nanoparticles attenuate inflammation and mitigate osteoarthritis progression
Treating osteoarthritis (OA) remains a major clinical challenge. Despite recent advances in drug discovery and development, no disease-modifying drug for knee OA has emerged with any notable clinical success, in part, due to the lack of valid and responsive therapeutic targets and poor drug delivery within knee joints. In this work, we show that the amount of secretory phospholipase A2 (sPLA2) enzyme increases in the articular cartilage in human and mouse OA cartilage tissues. We hypothesize that the inhibition of sPLA2 activity may be an effective treatment strategy for OA. To develop an sPLA2-responsive and nanoparticle (NP)–based interventional platform for OA management, we incorporated an sPLA2 inhibitor (sPLA2i) into the phospholipid membrane of micelles. The engineered sPLA2i-loaded micellar NPs (sPLA2i-NPs) were able to penetrate deep into the cartilage matrix, prolong retention in the joint space, and mitigate OA progression. These findings suggest that sPLA2i-NPs can be promising therapeutic agents for OA treatment.
- 9 April 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (15) , eabe6374
Open AccessPhospholipase A 2 inhibitor–loaded micellar nanoparticles attenuate inflammation and mitigate osteoarthritis progression
Treating osteoarthritis (OA) remains a major clinical challenge. Despite recent advances in drug discovery and development, no disease-modifying drug for knee OA has emerged with any notable clinical success, in part, due to the lack of valid and responsive therapeutic targets and poor drug delivery within knee joints. In this work, we show that the amount of secretory phospholipase A2 (sPLA2) enzyme increases in the articular cartilage in human and mouse OA cartilage tissues. We hypothesize that the inhibition of sPLA2 activity may be an effective treatment strategy for OA. To develop an sPLA2-responsive and nanoparticle (NP)–based interventional platform for OA management, we incorporated an sPLA2 inhibitor (sPLA2i) into the phospholipid membrane of micelles. The engineered sPLA2i-loaded micellar NPs (sPLA2i-NPs) were able to penetrate deep into the cartilage matrix, prolong retention in the joint space, and mitigate OA progression. These findings suggest that sPLA2i-NPs can be promising therapeutic agents for OA treatment.